Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 185 900 KRW -0.75% Market Closed
Market Cap: 42.9T KRW
Section:
 

Relative Value

The Relative Value of one Celltrion Inc stock under the Base Case scenario is hidden KRW. Compared to the current market price of 185 900 KRW, Celltrion Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Celltrion Inc Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

10.4
P/S
P/S
Price to Sales
10.4
vs History
61
vs Industry
37
Median 3Y
10.3
Median 5Y
11.5
Industry
7.9
Forward
9.7
More Details
55.1
P/E
P/E
Price to Earnings
55.1
vs History
52
vs Industry
0
Median 3Y
67.8
Median 5Y
58.9
Industry
24
Forward
47.4
More Details
50.1
P/OCF
P/OCF
Price to OCF
50.1
vs History
53
vs Industry
3
Median 3Y
50.3
Median 5Y
63.8
Industry
21.6
More Details
121.6
P/FCFE
P/FCFE
Price to FCFE
121.6
vs History
22
vs Industry
1
Median 3Y
86.1
Median 5Y
67.1
Industry
23.7
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
63
vs Industry
37
Median 3Y
2.4
Median 5Y
5.1
Industry
3.4
More Details
11
EV/S
EV/S
Enterprise Value to Sales
11
vs History
53
vs Industry
31
Median 3Y
10.5
Median 5Y
11.6
Industry
8.3
Forward
10.2
More Details
19.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
19.9
vs History
76
vs Industry
19
Median 3Y
21.5
Median 5Y
23.3
Industry
10.3
More Details
36
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
36
vs History
46
vs Industry
2
Median 3Y
35.9
Median 5Y
35.7
Industry
6.7
Forward
28.6
More Details
48.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
48.2
vs History
41
vs Industry
1
Median 3Y
49.1
Median 5Y
45.5
Industry
7.2
Forward
37.1
More Details
52.8
EV/OCF
EV/OCF
Enterprise Value to OCF
52.8
vs History
53
vs Industry
3
Median 3Y
52.6
Median 5Y
63.6
Industry
8.2
More Details
86.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
86.8
vs History
36
vs Industry
2
Median 3Y
70.5
Median 5Y
68.1
Industry
6.7
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
66
vs Industry
45
Median 3Y
2.1
Median 5Y
3.9
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Celltrion Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Celltrion Inc
KRX:068270
41T KRW 10.4 55.1 36 48.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
394.1B USD 6.6 167.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
168.9B USD 4.7 24.1 17.5 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
148.2B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111B USD 9.5 30.2 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.9B USD 5.1 15.9 15.1 17.1
AU
CSL Ltd
ASX:CSL
87.8B AUD 3.7 19.4 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.7B USD 17 1 256.1 165.2 200.4
NL
argenx SE
XBRU:ARGX
47B EUR 15.2 35.7 61.7 63.4
P/S Multiple
Revenue Growth P/S to Growth
KR
Celltrion Inc
KRX:068270
Average P/S: 3 101 236.9
10.4
17%
0.6
FR
Pharnext SCA
OTC:PNEXF
34 111 463.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
0.9
US
E
Epizyme Inc
F:EPE
2 065.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17
46%
0.4
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
P/E Multiple
Earnings Growth PEG
KR
Celltrion Inc
KRX:068270
Average P/E: 180.3
55.1
52%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
9%
1.8
AU
CSL Ltd
ASX:CSL
19.4
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 256.1
N/A N/A
NL
argenx SE
XBRU:ARGX
35.7
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBITDA: 39.9
36
35%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.5
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.2
N/A N/A
NL
argenx SE
XBRU:ARGX
61.7
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBIT: 46.8
48.2
57%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.5
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
200.4
N/A N/A
NL
argenx SE
XBRU:ARGX
63.4
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.